Holen Sie sich die Stockscreener-App
16.98
0.93%
-0.16
Schlusskurs vom Vortag:
$17.14
Offen:
$17.05
24-Stunden-Volumen:
161.57K
Relative Volume:
0.88
Marktkapitalisierung:
$715.03M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+4.43%
1M Leistung:
+1.01%
6M Leistung:
+145.02%
1J Leistung:
+0.00%
1-Tages-Spanne:
$16.36
$17.33
1-Wochen-Bereich:
$15.82
$18.29
52-Wochen-Spanne:
$5.83
$26.25
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Firmenname
Zenas Biopharma Inc
Sektor
Branche
Telefon
857-271-2954
Adresse
852 WINTER STREET, SUITE 250, WALTHAM
Vergleichen Sie ZBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
16.98 | 737.77M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-20 | Eingeleitet | Wedbush | Outperform |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Citigroup | Buy |
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Zenas Biopharma Inc Aktie (ZBIO) Neueste Nachrichten
Is Zenas BioPharma Inc.’s growth already priced in2025 Breakouts & Breakdowns & High Accuracy Trade Signal Alerts - khodrobank.com
What MACD and RSI say about Zenas BioPharma Inc.July 2025 Retail & Technical Confirmation Trade Alerts - Newser
Real time breakdown of Zenas BioPharma Inc. stock performanceRecession Risk & Precise Buy Zone Tips - Newser
What machine learning models say about Zenas BioPharma Inc.Market Weekly Review & Weekly Stock Performance Updates - Newser
Royalty Pharma's Strategic Position in the Biopharma Royalty Space - AInvest
Technical signs of recovery in Zenas BioPharma Inc.Weekly Stock Report & Weekly Setup with High ROI Potential - Newser
Is Zenas BioPharma Inc. still a buy after recent gainsWeekly Investment Report & Reliable Entry Point Trade Alerts - beatles.ru
How moving averages guide Zenas BioPharma Inc. tradingWeekly Trade Recap & Precise Trade Entry Recommendations - Newser
Chart based exit strategy for Zenas BioPharma Inc.Weekly Market Report & Weekly Top Gainers Alerts - Newser
Will Zenas BioPharma Inc. price bounce be sustainable2025 Fundamental Recap & Accurate Entry/Exit Alerts - Newser
How to integrate Zenas BioPharma Inc. into portfolio analysis toolsGap Down & Community Driven Trade Alerts - Newser
What’s the RSI of Zenas BioPharma Inc. stock2025 Geopolitical Influence & Verified Swing Trading Watchlists - khodrobank.com
Using fundamentals and technicals on Zenas BioPharma Inc.Jobs Report & Expert Curated Trade Setups - Newser
Is Zenas BioPharma Inc. stock overvalued or fairly pricedJuly 2025 Catalysts & Short-Term Swing Trade Alerts - khodrobank.com
Can Zenas BioPharma Inc. hit a new high this month2025 Market Sentiment & Risk Managed Trade Strategies - Newser
Is Zenas BioPharma Inc. trading at a discountJuly 2025 Institutional & Entry Point Confirmation Signals - khodrobank.com
Zenas Biopharma shares fall 2.28% intraday as Royalty Pharma announces $2.0 billion offering. - AInvest
Pattern recognition hints at Zenas BioPharma Inc. upside2025 Retail Activity & Weekly High Momentum Picks - Newser
Strategic Funding Boost: Zenas BioPharma’s Partnership with Royalty Pharma Enhances Obexelimab’s Commercial Potential - TipRanks
Trend analysis for Zenas BioPharma Inc. this weekJuly 2025 Final Week & Growth-Oriented Investment Plans - Newser
What institutional flow reveals about Zenas BioPharma Inc.2025 Earnings Surprises & Fast Momentum Entry Tips - Newser
Is Zenas BioPharma Inc. meeting your algorithmic filter criteriaQuarterly Portfolio Summary & Weekly Setup with High ROI Potential - Newser
Zenas BioPharma secures $300M funding from Royalty Pharma for obexelimab royalties. - AInvest
Published on: 2025-09-03 01:34:16 - Newser
Using data filters to optimize entry into Zenas BioPharma Inc.Portfolio Value Summary & Daily Volume Surge Signals - Newser
Wuxi XDC offers up to 22.3 million shares at HK$58.85 each - AInvest
Tick level data insight on Zenas BioPharma Inc. volatility2025 Momentum Check & Expert Curated Trade Ideas - Newser
Sasol Limited shares rise 2.89% intraday after Royalty Pharma and Zenas BioPharma announced a $300 million funding deal for obexelimab. - AInvest
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Servier pays $200M upfront to Ideaya; Zymeworks ends work on T cell engager - Endpoints News
Lead Plaintiff Appointed in Zenas BioPharma Class Action — Here’s How You Can Recover Your Losses - TradingView
Beone Medicines Ltd. shares rise 8.81% premarket after Royalty Pharma and Zenas BioPharma enter into a $300 million funding agreement. - AInvest
Zenas Biopharma and Royalty Pharma enter into obexelimab funding agreement for up to $300 million - MarketScreener
Zenas BioPharma, Royalty Pharma Enter $300 Million Funding Agreement for Obexelimab - MarketScreener
Zenas BioPharma Secures Up To $300 Mln Funding From Royalty Pharma For Obexelimab - Nasdaq
Bolt Projects Holdings, Inc. shares rise 1.54% premarket after Royalty Pharma and Zenas BioPharma announced a $300 million funding deal for obexelimab. - AInvest
Zenas BioPharma Secures $300M Funding for Obexelimab - TipRanks
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million - citybiz
Zenas BioPharma, Royalty Pharma Partner for $300mln Obexelimab Funding Agreement - AInvest
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million - GlobeNewswire
Royalty Pharma provides up to $300 million to Zenas BioPharma for obexelimab - StreetInsider
Zenas BioPharma Secures Up to $300 Million Funding for Obexelimab Development and Potential IgG4-RD Launch - AInvest
Zenas BioPharma, Inc. and Royalty Pharma Enter into Obexelimab Funding Agreement for Up to $300 Million - MarketScreener
Quantitative breakdown of Zenas BioPharma Inc. recent moveEarnings Risk Report & Real-Time Volume Spike Alerts - Newser
Does Zenas BioPharma Inc. show high probability of reboundWeekly Risk Report & AI Forecast Swing Trade Picks - Newser
Will Zenas BioPharma Inc. outperform its industry peersWeekly Profit Analysis & Smart Investment Allocation Tips - khodrobank.com
Does Zenas BioPharma Inc. stock benefit from AI growthTrade Risk Report & Precise Buy Zone Tips - khodrobank.com
Can Zenas BioPharma Inc. reach all time highs this year2025 AllTime Highs & Safe Entry Trade Signal Reports - khodrobank.com
Can Zenas BioPharma Inc. deliver consistent dividendsEarnings Trend Report & Verified Entry Point Detection - khodrobank.com
Finanzdaten der Zenas Biopharma Inc-Aktie (ZBIO)
Es liegen keine Finanzdaten für Zenas Biopharma Inc (ZBIO) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Zenas Biopharma Inc-Aktie (ZBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Xiao Ting | Director |
Feb 07 '25 |
Buy |
7.76 |
10,000 |
77,600 |
47,000 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 04 '24 |
Buy |
9.98 |
45,000 |
449,100 |
241,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 03 '24 |
Buy |
10.76 |
25,000 |
269,000 |
196,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 18 '24 |
Buy |
15.00 |
7,500 |
112,500 |
168,655 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 19 '24 |
Buy |
14.57 |
2,500 |
36,425 |
171,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 18 '24 |
Buy |
17.91 |
10,000 |
179,100 |
1,662,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 20 '24 |
Buy |
18.45 |
5,000 |
92,270 |
1,672,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 19 '24 |
Buy |
17.89 |
5,000 |
89,450 |
1,667,039 |
| Enavate Sciences GP, LLC | 10% Owner |
Sep 16 '24 |
Buy |
17.00 |
882,353 |
15,000,001 |
3,761,359 |
| Lu Hongbo | Director |
Sep 13 '24 |
Buy |
17.00 |
58,823 |
999,991 |
58,823 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):